ORIC’s Rinzimetostat Shows Potential for Best-in-Disease Efficacy and Safety in Prostate Cancer—Phase 3 Trial Set for 2026
Market Chameleon (Wed, 1-Apr 7:06 AM)
Rinzimetostat Shows Promise Against Prostate Cancer Resistance—ORIC's AACR 2026 Presentations Highlight Key Preclinical Findings
Market Chameleon (Wed, 18-Mar 7:09 AM)
ORIC Pharmaceuticals Issues Inducement Equity Grants to Bolster Its Clinical Pipeline
Market Chameleon (Mon, 9-Mar 8:22 AM)
